Tu, 180 patient HCQ late treatment study: 17% lower mortality [p=0.81] https://c19p.org/tu
copied to clipboard
Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study
et al., Infectious Diseases & Immunity, doi:10.1097/ID9.0000000000000037
Retrospective 180 hospitalized COVID-19 patients in Sierra Leone, showing no significant difference with HCQ treatment in unadjusted results, however HCQ was significantly more likely to be used for severe patients (33% vs. 12%).
|
risk of death, 17.2% lower, RR 0.83, p = 0.81, treatment 6 of 37 (16.2%), control 28 of 143 (19.6%), NNT 30.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Tu et al., 1/13/2022, retrospective, Sierraleone, Africa, peer-reviewed, 11 authors, study period 31 March, 2020 - 11 August, 2020.
Contact:
cww302@126.com, jjzheng@vip.sina.com, stevesyllo@gmail.com.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.